243 related articles for article (PubMed ID: 32988971)
21. High intratumoral CD8
Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
[TBL] [Abstract][Full Text] [Related]
22. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF; van Riet J; Smits M; Zhu Y; Hamberg P; van der Heijden MS; Bergman AM; van Oort IM; de Wit R; Voest EE; Steeghs N; Yamaguchi TN; Livingstone J; Boutros PC; Martens JWM; Sleijfer S; Cuppen E; Zwart W; van de Werken HJG; Mehra N; Lolkema MP
Nat Commun; 2019 Nov; 10(1):5251. PubMed ID: 31748536
[TBL] [Abstract][Full Text] [Related]
23.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
24. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
25. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.
Lautert-Dutra W; M Melo C; Chaves LP; Crozier C; P Saggioro F; B Dos Reis R; Bayani J; Bonatto SL; Squire JA
Mol Cytogenet; 2024 May; 17(1):11. PubMed ID: 38704603
[TBL] [Abstract][Full Text] [Related]
27. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract][Full Text] [Related]
28. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
29. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
30. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract][Full Text] [Related]
31. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
[TBL] [Abstract][Full Text] [Related]
32. Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Fenor de la Maza MD; Chandran K; Rekowski J; Shui IM; Gurel B; Cross E; Carreira S; Yuan W; Westaby D; Miranda S; Ferreira A; Seed G; Crespo M; Figueiredo I; Bertan C; Gil V; Riisnaes R; Sharp A; Rodrigues DN; Rescigno P; Tunariu N; Liu XQ; Cristescu R; Schloss C; Yap C; de Bono JS
Eur Urol Oncol; 2022 Dec; 5(6):659-667. PubMed ID: 35491356
[TBL] [Abstract][Full Text] [Related]
33. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
34. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Paschalis A; Sheehan B; Riisnaes R; Rodrigues DN; Gurel B; Bertan C; Ferreira A; Lambros MBK; Seed G; Yuan W; Dolling D; Welti JC; Neeb A; Sumanasuriya S; Rescigno P; Bianchini D; Tunariu N; Carreira S; Sharp A; Oyen W; de Bono JS
Eur Urol; 2019 Oct; 76(4):469-478. PubMed ID: 31345636
[TBL] [Abstract][Full Text] [Related]
37. CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database.
Kobayashi K; Saito Y; Kage H; Fukuoka O; Yamamura K; Mukai T; Oda K; Yamasoba T
Jpn J Clin Oncol; 2023 Aug; 53(9):798-807. PubMed ID: 37357968
[TBL] [Abstract][Full Text] [Related]
38.
Schweizer MT; Ha G; Gulati R; Brown LC; McKay RR; Dorff T; Hoge ACH; Reichel J; Vats P; Kilari D; Patel V; Oh WK; Chinnaiyan A; Pritchard CC; Armstrong AJ; Montgomery RB; Alva A
JCO Precis Oncol; 2020; 4():382-392. PubMed ID: 32671317
[TBL] [Abstract][Full Text] [Related]
39. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
40. CD38 in Advanced Prostate Cancers.
Guo C; Crespo M; Gurel B; Dolling D; Rekowski J; Sharp A; Petremolo A; Sumanasuriya S; Rodrigues DN; Ferreira A; Pereira R; Figueiredo I; Mehra N; Lambros MBK; Neeb A; Gil V; Seed G; Terstappen L; Alimonti A; Drake CG; Yuan W; de Bono JS;
Eur Urol; 2021 Jun; 79(6):736-746. PubMed ID: 33678520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
